Clinical trial
Arimidex Observational: Reason for and Effect of Change From Tamoxifen
NCT00246961 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00246961 |
|---|---|
| Title | Arimidex Observational: Reason for and Effect of Change From Tamoxifen |
| Official title | Arimidex: Reason for and Effect of Change From Tamoxifen |
| Acronym | ARREST |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Breast Cancer |
| Enrollment | 200 |
| Start date | Jul 1, 2004 |
| First posted | Nov 1, 2005 |
| Last update posted | Oct 12, 2007 |
| Countries | Netherlands |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: